Retrospective Cohort Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. Dec 21, 2023; 29(47): 6111-6121
Published online Dec 21, 2023. doi: 10.3748/wjg.v29.i47.6111
Figure 1
Figure 1 Association between fecal calprotectin and endoscopic scores. A: Differences in fecal calprotectin (FC) levels between Mayo Endoscopic Subscore (MES) groups; B: Differences in the Ulcerative Colitis Colonic Index of Severity (UCCIS); C: Correlation with the Ulcerative Colitis Endoscopic Index of Severity; D: Relationship between FC and UCCIS; E: Correlation between FC and UCCIS. aP < 0.001.
Figure 2
Figure 2 Receiver-operating characteristic analysis of fecal calprotectin and Ulcerative Colitis Colonic Index of Severity for predicting Mayo Endoscopic Subscore 0. FC: Fecal calprotectin; UCCIS: Ulcerative Colitis Colonic Index of Severity.
Figure 3
Figure 3 Differences between fecal calprotectin and Ulcerative Colitis Colonic Index of Severity in terms of predicting relapse and the receiver-operating characteristic analysis for predicting relapse. A: Difference in fecal calprotectin (FC) levels between the relapse and remission groups; B: Difference in Ulcerative Colitis Colonic Index of Severity (UCCIS) between the relapse and remission groups; C: Receiver-operating characteristic analysis of FC and UCCIS for predicting relapse within 1 year. aP < 0.001. FC: Fecal calprotectin; UCCIS: Ulcerative colitis colonic index of severity.
Figure 4
Figure 4 Kaplan-Meier analysis of relapse-free rates. A: Mayo Endoscopic Subscore; B: Ulcerative Colitis Endoscopic Index of Severity; C: Fecal calprotectin levels; D: Ulcerative Colitis Colonic Index of Severity. FC: Fecal calprotectin; MES: Mayo endoscopic subscore; UCCIS: Ulcerative colitis colonic index of severity; UCEIS: Ulcerative colitis endoscopic index of severity.